Catalyst Pharmaceuticals Inc (CPRX)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses

CORAL GABLES, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq:...

Form 8-K - Current report

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Form 4 - Statement of changes in beneficial ownership of securities

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material